证券代码：301507 证券简称：民生健康 公告编号：2025-034 杭州民生健康药业股份有限公司 第二届董事会第九次会议决议公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 一、董事会会议召开情况 经全体董事审议，作出如下决议： (一) 审议通过了《关于参与技源集团首次公开发行股票战略配售的议案》 经审议，董事会认为：本次对外投资有利于深化并巩固公司与技源集团互信 互利的战略合作关系，有助于有效整合双方在技术支持、业务协同等领域的优质 资源与核心优势，优化产业资源的高效配置与协同发展，有利于提升公司行业影 响力与竞争力，优化配置产业资源，符合公司整体发展战略、业务布局和全体股 东的利益。因此，同意公司作为战略投资者以自有资金参与技源集团首次公开发 行股票并在主板上市的战略配售，认购金额不超过人民币 1,500 万元，并同意授 权公司经营管理层在战略配售认股协议约定范围内办理战略配售认股协议涉及 的相关事宜。 具体内容详见公司同日披露于巨潮资讯网（www.cninfo.com.cn）的《关于参 与技源集团首次公开发行股票战略配售的公告》（公告编号： ...

证券代码：301507 证券简称：民生健康 公告编号：2025-035 杭州民生健康药业股份有限公司 关于参与技源集团首次公开发行股票战略配售 的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 特别提示： 1、为加强杭州民生健康药业股份有限公司（以下简称"公司"）与技源集团 股份有限公司（以下简称"技源集团"、"投资标的"）之间的战略合作关系，公司 计划作为战略投资者以自有资金参与技源集团首次公开发行股票并在主板上市 的战略配售，认购金额不超过人民币1,500万元。 公司于 2025 年 7 月 2 日召开第二届董事会第九次会议，审议通过了《关于 参与技源集团首次公开发行股票战略配售的议案》，同意公司作为战略投资者以 自有资金参与技源集团首次公开发行股票并在主板上市的战略配售，认购金额不 超过人民币 1,500 万元，并同意授权公司经营管理层在战略配售认股协议约定范 围内办理战略配售认股协议涉及的相关事宜。 根据《深圳证券交易所创业板股票上市规则》《上市公司重大资产重组管理 办法》等相关规定，本次对外投资所涉事项不构成关联交易，不构成《上市公司 重 ...

证券代码：301507 证券简称：民生健康 公告编号：2025-033 杭州民生健康药业股份有限公司 关于非独立董事辞职暨选举第二届董事会职工代表 董事的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 杭州民生健康药业股份有限公司（以下简称"公司"）于2025年5月15日召开 了2024年年度股东大会，审议通过了《关于修订<公司章程>的议案》，根据修订 后的《杭州民生健康药业股份有限公司章程》（以下简称"《公司章程》"），公司 不再设置监事会，同时董事会设职工代表董事一名，职工代表董事由公司职工通 过职工代表大会、职工大会或者其他形式民主选举产生。 一、关于非独立董事辞职的情况说明 公司于近日收到公司非独立董事刘丽云女士提交的书面辞职报告，刘丽云女 士因公司内部安排调整原因，辞去公司第二届董事会非独立董事职务，其非独立 董事职务原定任期至公司第二届董事会任期届满之日止，辞职后刘丽云女士仍然 担任公司副总经理职务。 截至本公告披露日，刘丽云女士未直接持有公司股份，通过杭州景牛企业管 理合伙企业（有限合伙）间接持有公司股份，占公司总股本的0.03%。其 ...

一、 回购股份的基本情况 公司于 2025 年 3 月 19 日召开第二届董事会第七次会议，审议通过《关于以 集中竞价交易方式回购公司股份的议案》，同意公司通过集中竞价交易方式以自 有资金回购部分社会公众股份，用于股权激励。回购价格不超过人民币 19.80 元 /股；预计回购股份数量为 130 万-145 万股，预计回购资金总额不超过人民币 2,871.00 万元，具体以实际回购情况为准；回购实施期限为自董事会审议通过本 次回购方案之日起 12 个月内。 具体内容详见公司于 2025 年 3 月 21 日、2025 年 3 月 31 日在巨潮资讯网 （www.cninfo.com.cn）披露的《关于以集中竞价交易方式回购公司股份方案的公 告》（公告编号：2025-004）、《回购报告书》（公告编号：2025-007）。 二、 公司实施回购方案的进展情况 证券代码：301507 证券简称：民生健康 公告编号：2025-032 杭州民生健康药业股份有限公司 关于以集中竞价交易方式回购公司股份的进展公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 重要内容 ...

Core Insights - The second China Pharmaceutical Health Industry Development Conference was held in Zibo, focusing on innovation and integration in the pharmaceutical health sector [1][3] - The conference gathered over 2,000 industry elites, including academicians and business representatives, to discuss innovative development paths for the pharmaceutical health industry [3] Group 1: Conference Themes and Discussions - The conference theme was "Breaking Boundaries, New Integration, New Intelligence, Exploring New Models," emphasizing the need for systemic innovation in healthcare [3] - Academician Yu Jinming highlighted that high-quality hospital development relies on systemic innovation beyond mere technological breakthroughs [3] - Academician Huang Zhengming pointed out that the future of the pharmaceutical industry depends on the cultivation of "new quality productivity" in response to aging and chronic disease burdens [3] Group 2: Major Projects and Initiatives - Three significant healthcare projects were launched, including the Chronic Disease Prevention Workstation and specialized centers for pancreatic cancer and diabetes treatment [4] - These projects will leverage resources from various sectors to establish a four-tier management network and promote smart platforms and regional demonstration networks [4] Group 3: Forum and Activities - The conference featured six thematic forums covering topics such as AI empowerment, traditional Chinese medicine, minimally invasive innovations, and chronic disease prevention [4] - A "Specialty Enterprise Study" activity allowed participants to visit local pharmaceutical and healthcare facilities, while a volunteer service event provided free health consultations to the public [4] Group 4: Zibo's Role in the Industry - Zibo showcased its strong pharmaceutical industry foundation and innovative environment, demonstrating its commitment to becoming a hub for pharmaceutical health industry innovation [5] - The signing of projects and continuous resource aggregation in Zibo is expected to bring new development opportunities for the pharmaceutical health industry both locally and nationally [5]

Investment Rating - The report assigns a "Buy" rating for the company, marking its first coverage [1]. Core Views - The company is entering a new phase of product launches, with significant growth potential in its probiotic and therapeutic drug segments. The report anticipates a robust increase in revenue and net profit over the next few years, driven by new product introductions and market expansion [5][6]. Summary by Sections Company Overview - The company, Minsheng Health, has a rich history dating back to 1926 and is known for its flagship product, 21 Jinweita, which was the first multivitamin OTC product in China. The company has shown steady growth with a CAGR of 13% in revenue and 18% in net profit from 2018 to 2024 [5][10][12]. Market and Industry Analysis - The OTC market in China is experiencing significant growth, with the market size increasing from 128.9 billion yuan in 2016 to 221.4 billion yuan in 2024, reflecting a CAGR of 7%, which is higher than the global average of 4% [5][37]. The vitamin and mineral segment is expected to maintain a growth rate of around 9% in the coming years, supported by an aging population and increasing health awareness among consumers [45][50]. Product Development and Growth Potential - The company is expanding its product matrix, with a focus on traditional vitamins and minerals, probiotics, and therapeutic drugs. The report highlights the expected launch of new products, including Minoxidil for hair loss and Varenicline for smoking cessation, which are projected to contribute significantly to revenue starting in 2025 [5][18][19]. Financial Projections - The report forecasts the company's total revenue to reach approximately 797.38 million yuan in 2025, with a year-on-year growth of 24.35%. Net profit is expected to be around 111.37 million yuan, reflecting a growth rate of 21.27% [1][5]. The company's P/E ratio is projected to decrease from 57.79 in 2023 to 44.44 in 2025, indicating an attractive valuation as growth accelerates [1]. Management and Governance - The company has a stable and experienced management team, with a clear ownership structure that supports strategic continuity. The major shareholder is Hangzhou Minsheng Pharmaceutical, ensuring strong control over the company's direction [18][20]. The introduction of an equity incentive plan in 2024 aims to enhance team motivation and align interests with long-term growth targets [22].

Core Viewpoint - Minsheng Health (301507) is actively expanding its business in the fields of treatment-type OTC drugs and medical aesthetics, demonstrating strategic determination and confidence in its growth prospects [1] Group 1: Business Development and Strategy - The company is focusing on the medical aesthetics business to respond to the transformation needs of pharmacy channels, promoting its products through model stores and counter placements in key pharmacies nationwide [1] - Minsheng Health's main product, 21 Jin Weita Multivitamin Tablets, is a non-prescription drug that is less affected by the challenges faced by pharmacy channels, with plans to expand its network and accelerate new product launches [2] - The company aims to become a benchmark enterprise in the vitamin and mineral sector, leveraging its strong R&D capabilities and product innovation to meet diverse health needs across different age groups [5] Group 2: Financial Performance - In Q1 2025, the company achieved revenue of 271 million yuan, a year-on-year increase of 15.70%, and a net profit of 61.12 million yuan, up 7.10% year-on-year, with total assets reaching 1.977 billion yuan, a growth of 13.32% [3] Group 3: Market Trends and Opportunities - The dietary supplement market in China has shown steady growth, with the market size increasing from 63.642 billion yuan in 2009 to 225.341 billion yuan in 2023, reflecting a compound annual growth rate (CAGR) of 8.47% from 2013 to 2023 [4] - The company is well-positioned to capitalize on the growing health awareness among the population and the potential for increased per capita consumption in the dietary supplement market [4] Group 4: Product and Brand Strategy - Minsheng Health has established a comprehensive health brand matrix, with "21 Jin Weita" leading in the vitamin and mineral sector, while also focusing on treatment-type OTC drugs and probiotics to meet specific health needs [5] - The company is committed to a brand rejuvenation strategy that targets all age groups, with a particular focus on the elderly demographic, offering products designed for joint treatment and anti-aging [6][7] Group 5: Technological Advancements - The company is advancing its digital and automated manufacturing capabilities, with ongoing projects aimed at enhancing production efficiency and quality control [7] - By implementing a standardized quality management system and strengthening supplier management, the company aims to ensure sustainable development and high-quality product offerings [7]

Group 1: Company Overview - The company, Minsheng Health, focuses on vitamins, minerals, probiotics, and therapeutic drugs, with a strong emphasis on expanding its product lines and market presence [2][3]. Group 2: Market Challenges and Strategies - The sales of vitamin and mineral products in offline channels have declined, but the impact on the company's OTC product, 21 Jinweita Multi-Element Tablets, is relatively limited [3]. - To address the challenges in pharmacy channels, the company plans to expand its terminal network and accelerate the launch of new products to become a leader in the vitamin and mineral sector [3]. Group 3: Probiotic Business Structure - The probiotic business is managed through subsidiaries, with teams split between Shandong for B2B sales and Hangzhou for B2C sales and R&D [3][4]. - The company has over 6,500 strains in its proprietary "Yanhuang Strain Library," with nearly 50 patented strains, focusing on functional strains with proven effects [3]. Group 4: Product Development and Target Markets - The company is developing products targeting both young and elderly consumers, with specific products for joint treatment and anti-aging aimed at the aging population [5][6]. - The company has plans for new product launches in areas such as joint treatment, anti-aging, and sleep improvement, although these require careful planning [6]. Group 5: Sales Dynamics - The company's revenue is concentrated in the first quarter due to inventory and accounts receivable clearance at year-end, leading to increased shipments to meet demand during the Spring Festival [6].

证券代码：301507 证券简称：民生健康 公告编号：2025-031 杭州民生健康药业股份有限公司 关于公司控股子公司取得发明专利证书的公告 本公司及董事会全体成员保证信息披露内容真实、准确和完整，不存在任何 虚假记载、误导性陈述或者重大遗漏。 一、取得发明专利的基本情况 近日，杭州民生健康药业股份有限公司（以下简称"公司"）控股子公司民 生中科嘉亿（山东）生物工程有限公司收到国家知识产权局颁发的一项发明专利 证书，具体情况如下： 发明名称：改善肌少症性肥胖的乳酸乳球菌乳亚种 JYLL-51 及其菌剂和应 用 证书号：第 7996686 号 专利类型：发明专利 专利号：ZL 2025 1 0286088.6 专利申请日：2025 年 3 月 12 日 专利权人：民生中科嘉亿（山东）生物工程有限公司 授权公告日：2025 年 6 月 13 日 专利权期限：二十年，自申请日起算 本发明专利涉及微生物技术领域，具体涉及改善肌少症性肥胖的乳酸乳球菌 乳亚种 JYLL-51 及其菌剂和应用。本发明专利提供一种乳酸乳球菌乳亚种 JYLL- 51，由该菌株制备的乳酸乳球菌乳亚种 JYLL-51 菌剂既能提高骨骼肌重量和力 ...

Group 1: Company Overview - The company is engaged in the health and functional food sector, focusing on probiotics and other health products [2] - The first quarter of 2025 showed stable growth in the vitamin and mineral segment, while the probiotics segment is expected to see significant changes due to strategic partnerships [3] Group 2: Business Segments Performance - The probiotics segment had low revenue as of December 31, 2024, but is anticipated to grow due to collaborations with Zhongke Jiayi [3] - The therapeutic drug segment currently has only one product, aluminum magnesium carbonate suspension, with limited revenue contribution expected from upcoming products like minoxidil [3] - The company is exploring new sales models in the Minsheng Tongchun segment, which is still in the early stages and has not significantly contributed to overall performance [3] Group 3: Product Development and Market Strategy - The company plans to launch minoxidil and vancomycin in Q3 2025, with different sales strategies for each product [3] - OTC products face greater regulatory challenges compared to blue hat products, leading to higher barriers to entry [3] - The company aims to expand its market penetration for new vitamin and mineral products, which currently have low market share [5] Group 4: International Expansion Plans - The company is considering international markets for its products, aiming to meet similar nutritional needs as those in China [4] - There is a focus on introducing mature overseas formulas to enhance product offerings [4] Group 5: Competitive Landscape - The company intends to differentiate its minoxidil product from existing competitors in the market through a unique competitive strategy [5] - The core product, 21 Jin Weita, has seen slowed growth, prompting a strategy to penetrate lower-tier markets [5]